Open Access
- 12 January 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 172
Abstract
Breast cancer, with its global prevalence and impact on women’s health, necessitates effective early detection and accurate staging for optimal patient outcomes. Traditional imaging modalities such as mammography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging (MRI) play crucial roles in local-regional assessment, while bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) aid in evaluating distant metastasis. Despite the proven utility of 18F-FDG PET/CT in various cancers, its limitations in breast cancer, such as high false-negative rates for small and low-grade tumors, have driven exploration into novel targets for PET radiotracers, including estrogen receptor, human epidermal growth factor receptor-2, fibroblast activation protein, and hypoxia. The advent of PET/MRI, which combines metabolic PET information with high anatomical detail from MRI, has emerged as a promising tool for breast cancer diagnosis, staging, treatment response assessment, and restaging. Technical advancements including the integration of PET and MRI, considerations in patient preparation, and optimized imaging protocols contribute to the success of dedicated breast and whole-body PET/MRI. This comprehensive review offers the current technical aspects and clinical applications of PET/MRI for breast cancer. Additionally, novel targets in breast cancer for PET radiotracers beyond glucose metabolism are explored.Keywords
Funding Information
- Konkuk University Medical Center (This work was supported by Konkuk University Medical Center Research Grant 2022.)
This publication has 79 references indexed in Scilit:
- Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CTEuropean Journal of Radiology, 2015
- A Practical Guide to MR Imaging Safety: What Radiologists Need to KnowRadioGraphics, 2015
- F-18 Fluoromisonidazole for Imaging Tumor Hypoxia: Imaging the Microenvironment for Personalized Cancer TherapySeminars in Nuclear Medicine, 2015
- Diffusion‐weighted imaging: Effects of intravascular contrast agents on apparent diffusion coefficient measures of breast malignancies at 3 teslaJournal of Magnetic Resonance Imaging, 2015
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Can 18F-FDG PET improve the evaluation of suspicious breast lesions on MRI?European Journal of Radiology, 2014
- Integrated PET/MRJournal of Magnetic Resonance Imaging, 2013
- First characterization of a digital SiPM based time-of-flight PET detector with 1 mm spatial resolutionPhysics in Medicine & Biology, 2013
- Performance Measurements of the Siemens mMR Integrated Whole-Body PET/MR ScannerJournal of Nuclear Medicine, 2011
- Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)European Journal of Nuclear Medicine and Molecular Imaging, 2009